Implementing artificial intelligence (AI) has transformed clinicians' and health systems' ability to screen for and distinguish forms of cardiorenalmetabolic disease.
In the realm of cardiorenalmetabolic disease, saying a patient either has or does not have a condition may simplify their circumstances too much, argued Jaime Murillo, MD, senior vice president and chief medical officer, Medical Affairs, UnitedHealth Group. In many cases, disease severity falls on a spectrum and requires more careful care approaches.
The implementation of artificial intelligence (AI) into clinical settings has enhanced patient screenings and assessments, redefined notions of “disease,” shed light on predictive pathways, and helped guide clinical decisions. In this interview with The American Journal of Managed Care®, Murillo spoke more to these topics and the value of integrating AI into health care.
This transcript has been lightly edited; captions were auto-generated.
Transcript
What role(s) can artificial intelligence integration play in improving care delivery and outcomes?
Artificial intelligence is going to change the world [of] health care. Period. It's already changing in many ways, but I would submit that we haven't even seen the actual capabilities and extent of what AI can do in health care. Right now, we see efforts like predictive analytics to identify high-risk patients. We see work on what we call CDS, which is clinical decision support, where AI can come in and tell doctors, “Hey, this patient will benefit from a mammogram or a colon cancer screening,” and so on. We also see efforts around the use of AI to reduce administrative burden. For instance, payers use it for claim approvals, not denials. It's important to clarify that AI is not denying, it's approving, the ones that are streamlined.
We also see AI in imaging now. We can detect disease more accurately through AI reading EKGs [electrocardiograms], CT scans, echocardiograms, mammograms, and so on. So there's a lot of opportunity, but there are 2 areas where I see an opportunity for AI. Number 1, bringing personalized care to people, because now you can accumulate tons of data into the patient's information and then give the provider information about the patient that will allow them to be more personalized in terms of their care.
The second area where you see a major opportunity is in redefining disease through the AI. Let me explain that right now, we have an approach that is very binary to health care: someone has diabetes or doesn't have diabetes. The reality is, it's all within the spectrum. Disease goes from all the way normal to a very complicated condition. That spectrum is what AI has an opportunity to define through patterns. If today we say, if you have a hemoglobin A1C of, let's say, 6.3, you're not diabetic. If it's 6.5, you're diabetic. The reality is that 6.3 may actually have a higher risk than the 6.5 because of a host of other conditions that we're still not familiar with.
Long-Term Data Show Favorable Survival Outcomes With G-Clb in Treatment-Naive CLL
May 1st 2025Participants in the CLL11 trial and a smaller group of patients followed after study completion showed improved overall survival with obinutuzumab and chlorambucil (G-Clb) compared with chemotherapy plus rituximab or chemotherapy alone for chronic lymphocytic leukemia (CLL).
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen